#87 - Rick Johnson, M.D.: Fructose—The common link in high blood pressure, insulin resistance, T2D, & obesity?

Episode Summary

Executive Summary: Peter Atiyah interviews nephrologist Rick Johnson on the biology of fructose, uric acid, salt, and metabolic disease. Johnson argues that fructose is not just a dietary sugar but a survival signal that can drive fat storage, insulin resistance, hypertension, and fatty liver via ATP depletion and uric acid. The discussion also reframes salt as a water-balance problem, highlights inflammation and autoimmunity in hypertension, and reviews emerging fructokinase-targeting therapies.

Main Topics: Fructose as a driver of metabolic disease (Priority: 5/5): Johnson explains that fructose metabolism uniquely depletes cellular ATP, raises uric acid, and promotes fat storage, insulin resistance, fatty liver, and hypertension. He argues this pathway underlies much of modern metabolic syndrome. Salt, water, and blood pressure (Priority: 5/5): The conversation challenges the simplistic 'salt amount' model of hypertension, emphasizing serum sodium concentration, osmolality, and the balance between salt and water as key determinants of acute blood pressure rises. Uric acid as a central mediator (Priority: 5/5): Johnson describes uric acid as more than a gout marker: it is implicated in blood pressure, kidney disease, insulin resistance, and fructose-driven metabolic dysfunction, with allopurinol potentially beneficial beyond gout. Evolutionary origin of human fructose sensitivity (Priority: 4/5): A detailed evolutionary story links a uricase mutation in apes to enhanced fat storage from fruit during climate stress, helping explain why humans are unusually sensitive to fructose and prone to uric acid elevation. Mechanistic biochemistry: ATP, AMPD, and AMPK (Priority: 5/5): The interview dives into the fork between AMPD and AMPK pathways after ATP depletion. AMPD promotes fat storage and disease, while AMPK supports energy burning and metabolic health. Artificial sweeteners, umami, and dietary strategy (Priority: 3/5): Atiayah and Johnson discuss diet soda as the lesser evil versus sugar, the uncertain safety of some sweeteners, and the possible metabolic effects of umami-rich, purine-heavy foods and beer. Therapeutic implications and clinical practice (Priority: 4/5): Johnson describes using uric acid thresholds to guide allopurinol treatment, notes risks like allopurinol hypersensitivity, and mentions fructokinase inhibitors in development for fatty liver and related disease.

Key Arguments: Fructose is metabolically distinct from glucose because it lowers intracellular ATP before restoring it, triggering a survival program that favors fat storage, hunger, and reduced energy expenditure. Uric acid is not merely a gout biomarker; soluble uric acid appears to mediate fructose’s effects on blood pressure, insulin resistance, fatty liver, and kidney injury. High salt intake raises blood pressure mainly when it increases serum sodium/osmolality; water can blunt this effect, making salt-water balance more important than salt quantity alone. Primary hypertension may involve kidney inflammation and even autoimmune responses, including reactions to heat shock proteins. The evolutionary loss of uricase in humans likely increased sensitivity to fructose and improved fat storage during famine, but now contributes to metabolic disease in an environment of abundant sugar. Fructose can be generated endogenously from glucose via aldose reductase, meaning high-glycemic diets may still drive fructose-like metabolic effects even without added fructose. Pair-feeding studies show fructose can cause fatty liver, insulin resistance, and hypertension even without weight gain, undermining the idea that only excess calories matter. Artificial sweeteners are likely safer than sugar in metabolic terms, though their long-term safety is not fully settled. Fructokinase inhibition is a promising therapeutic strategy, with phase 2/3 development mentioned for fatty liver disease.

Data Points: Johnson publications: 700-800+ - Peter Atiyah describes Johnson as having well over 700, approaching 800 publications. Years as division chief: 17 years - Johnson is described as having spent the last 17 years as a division chief across three medical schools. Salt-induced blood pressure rise: ~6 mmHg - Johnson says serum sodium rising from about 140 to 142-143 can acutely raise blood pressure by about six millimeters. Blood pressure threshold for sharply increased stroke risk: 160-180 mmHg - He notes a major inflection point where stroke and mortality risk rise dramatically. Uric acid risk threshold: >5.5 mg/dL - Johnson says risks for prediabetes, insulin resistance, hypertension, and kidney disease begin to rise above this level. Allopurinol hypersensitivity in Asians: 3%-4% - He cites higher allergic reaction risk in Asian patients. Allopurinol hypersensitivity in African-Americans: ~2% - He cites intermediate risk in African-American patients. Allopurinol hypersensitivity in Caucasians: ~0.5% - He cites lower risk in Caucasian patients. Fructose in high-sugar animal diet study: 20% of calories - Johnson references a rat study using a high-sugar, low-calorie diet with 20% of energy from fructose. Fructose effect timing: First 4 hours - He says triglycerides, uric acid, and blood pressure changes are best seen in the first four hours after ingestion. Fructose metabolism and ATP depletion: 40%-50% drop - He states cellular ATP can fall by 40-50% when fructose is metabolized unregulated by fructokinase. Processed foods with sugar/HFCS: ~70% - He says about 70% of packaged foods contain sugar or high fructose corn syrup. Natural fruit diet target for fatty liver: 10 g/day fructose - He says patients with non-alcoholic fatty liver disease are often restricted to 10 grams per day from whole fruit only. Fruit in a large apple: ~10 g fructose - He estimates a large apple may contain about 10 grams of fructose. Fructokinase inhibitor trial status: Phase 2 completed; phase 3 planned - He mentions Pfizer’s fructokinase inhibitor showing success in fatty liver and moving forward. Allopurinol vs febuxostat trial: CARES study had no placebo arm - He argues the cardiovascular comparison is hard to interpret because the trial lacked a placebo group.

Pivotal Quotes: "“It isn't really the salt amount that makes a difference? But the salt concentration.”" — Rick Johnson: Explaining why serum sodium/osmolality, not just total salt intake, drives acute blood pressure changes. "“When you metabolize fructose, the energy in the cell falls before it goes up.”" — Rick Johnson: Describing the unique ATP-depleting effect of fructose metabolism that triggers fat-storage biology. "“If we could reduce our fructose intake, I think it would have a huge, huge effect.”" — Rick Johnson: Summarizing his view that lowering fructose exposure could substantially reduce metabolic disease burden.

Implications: The episode argues that modern metabolic disease is driven less by calories alone than by fructose biology, uric acid, and salt-water balance. For listeners, the practical takeaways are to avoid sugary drinks, limit high-glycemic carbs, hydrate with salty meals, and consider uric acid as a meaningful risk marker.